NCT02179359Terminated
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
Source: ClinicalTrials.gov · Last updated 3 Mar 2025
Brief summary (registry, in English)
This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.
- Status (registry)
- Terminated
- Study type
- Interventional
- Enrollment
- 38 (actual)
- First submitted
- 27 Jun 2014
- Start date
- 2 Sept 2014
- Primary completion date
- 21 Nov 2024
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Diseases
- Sickle cell disease, Thalassaemia
- NCT number
- NCT02179359
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- active, uncontrolled infection
- HIV positive
Other
- pregnant or breastfeeding
Who the study is looking for
- Diagnosis of Sickle Cell Disease, Thalassemia, Diamond Blackfan Anemia or other non-malignant hematologic disorders for which a stem cell transplant is indicated
- Acceptable stem cell source identified
- Performance status of ≥ 70% (Karnofsky),or ≥ 70 (Lansky play score)
- Creatinine <2.0 mg/dl for adults or glomerular filtration rate > 50 ml/min for children
- Bilirubin, Aspartate Aminotransferase, Alkaline phosphatase <5 times the upper limit of institutional normal
- Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 40%
Age in the registry: - to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Minnesota Medical Center, Fairview Coordinator of this site? Confirm its status | Minneapolis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.